Meyka Pro banner
Suzhou Ribo Life Science Co

Suzhou Ribo Life Science Co (6938.HK) Stock Competitors & Peer Comparison

See (6938.HK) competitors and their performances in Stock Market.

6938.HKHKSE
HealthcareBiotechnology
HK$55.60
HK$4.80(9.45%)
Hong Kong Market is Open · 15:59

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
6938.HKHK$54.80+7.87%9.2B-27.11-HK$1.99N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$194.60+0.83%265B88.84HK$2.21N/A
2269.HKHK$39.22+1.03%160.9B30.39HK$1.28N/A
1801.HKHK$91.65-0.54%160.6B169.64HK$0.54N/A
6990.HKHK$525.00+2.64%120.6B-256.32-HK$2.02N/A
9926.HKHK$104.90+10.89%91B-73.72-HK$1.34N/A
3347.HKHK$38.00+1.23%46.3B39.06HK$0.98+0.38%
1530.HKHK$17.64+4.26%43.2B4.50HK$3.84+1.45%
6821.HKHK$119.20-2.61%42.9B38.98HK$3.05+1.26%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

6938.HK vs 4332.HK Comparison July 2026

6938.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6938.HK stands at 9.2B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 6938.HK is priced at HK$54.80, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6938.HK currently has a P/E ratio of -27.11, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 6938.HK's ROE is N/A, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 6938.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6938.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions